Skip to main
PSTV

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics Inc is positioned favorably due to its focus on developing innovative treatments for cancer, particularly its lead candidate, rhenium (186Re) obisbemeda, targeting high-unmet needs in central nervous system cancers. The recent constructive discussions with the FDA regarding a pivotal trial for rhenium (186Re) obisbemeda, particularly for leptomeningeal metastases, highlight a potential accelerated approval pathway, underscoring the therapy's significant clinical promise. Additionally, the successful public offering that raised approximately $15 million strengthens Plus Therapeutics's balance sheet, enhancing its operational flexibility and supporting ongoing research and development endeavors.

Bears say

The analysis indicates a negative outlook for Plus Therapeutics, primarily due to a reduced 12-month price target for the stock, which has been decreased from $2.00 to $1.00 per diluted share following a recent equity offering and the anticipated exercise of associated warrants. This adjustment reflects concerns regarding the financial impact of these developments on the company’s market valuation. Additionally, there is uncertainty surrounding the efficacy of rhenium (186Re) obisbemeda in clinical studies, as varying median overall survival rates reported in previous studies could hinder reliable comparisons and complicate future performance assessments.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.